Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial

ALIMTA Plus Gemcitabine as Front-line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase II Clinical Trial

The purposes of this study are to determine:

1. The safety of Pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs.
2. Whether Pemetrexed plus Gemcitabine can help patients with non-small cell lung cancer live longer.
3. Whether Pemetrexed plus Gemcitabine can make the tumor smaller or disappear, and for how long.
4. To see if patients feel better while taking Pemetrexed plus Gemcitabine.

Inclusion Criteria:

• Diagnosis of Non-Small Cell Lung Cancer that can be treated with chemotherapy.
• Have received no prior chemotherapy for Non-Small Cell Lung Cancer.
• Have at least one measurable lesion.
• Have an adequate performance status.
• Sign an informed consent.

Exclusion Criteria:

• A female who is pregnant or breastfeeding.
• Treatment with an investigational drug within the last 30 days, previously completed or withdrawn from this study or any other study investigating Pemetrexed.
• Treatment with radiation therapy within the last 4 weeks.
• Brain metastasis that is uncontrolled.
• Active infection or other serious condition.